Dosni Roha Indonesia Tbk. PT (ZBRA)

Overview

Kazia Therapeutics Limited is a biotechnology entity focused on the development of anti-cancer drugs, showcasing a dynamic approach in the treatment of various cancers. Originally established in 1994 as Novogen Limited, the company underwent a significant rebranding to Kazia Therapeutics Limited in November 2017, signifying a renewed focus on its innovative therapeutic solutions. Operating from its headquarters in Sydney, Australia, Kazia has positioned itself as a pioneer in the oncology sector, leveraging cutting-edge research to target some of the most challenging forms of cancer through its advanced drug development programs.

Products and Services

• Paxalisib

Kazia's flagship product, Paxalisib, is a groundbreaking inhibitor of the PI3K/AKT/mTOR pathway, crafted with precision to penetrate the brain and potentially treat a range of cancers including glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. Its development underscores Kazia’s commitment to targeting some of the most aggressive and difficult-to-treat cancers, providing hope for patients worldwide.

• EVT801

Expanding its oncology pipeline, Kazia is also developing EVT801, a novel small molecule inhibitor specifically targeting the vascular endothelial growth factor receptor 3 (VEGFR3). This therapeutic is designed to inhibit tumor growth by targeting the blood vessels that feed them, representing another facet of Kazia’s strategy to combat cancer through innovative and targeted therapies.